




Treatment of pleural empyema



I have no conflicts of interest
to report



DEFINITIONS





Parapneumonic effusion is any
pleural
effusion associated with a
suppurative parenchymal lung
disease



SIMPLE Parapneumonic Effusion is an uninfected, free-flowing fluid collection



COMPLICATED Parapneumonic
Effusion is an early infected fluid
collection, prone to develop
loculations by fibrinous septations



EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS

Thoracic EMPYEMA is a collection
of frank **PUS**
within the pleural space



Pleural infection: 80,000 cases/year UK and USA

High associated morbidity and mortality:

20% pts with empyema die

20% pts with empyema require surgery



The incidence of empyema
continues to grow
with an estimated 65,000 pts
affected/year, and an
annual cost of
500 million \$ per year



Pleural infection most commonly occurs in paediatric and elderly population

RISK FACTORS:

(same for pneumonia)

diabetes mellitus

immunosuppression

corticosteroid use

gastro-oesophageal reflux

alcohol

intravenous drug abuse





EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS

Physiology of the pleura



In health:

Pleural fluid volume < 1 ml

(film ~ 10 μm between visceral and parietal)

It contains:

proteins at the same concentration


of the *interstitial fluid*

small number of cells

(mesothelial cells, lymphocytes, macrophages)

LDH (lactate dehydrogenase)

pH: ~7.6






In health:

Normal Pleural Fluid values

Volume:	0.1 to 0.2 ml/kg
Cells per mm ³ :	1000 to 5000
Mesothelial cells:	3% to 70%
Monocytes:	35% to 70%
Lymphocytes:	2% to 30%
Protein:	1-2 g/dl
Albumin:	50% to 70%
Glucose:	similar to plasma levels
LDH:	<50% plasma level
pH:	~7.6



1962:
The American Thoracic Society

3 stages:

exudative stage (*acute*)

fibrinopurulent stage

organized stage with scar tissue
(pleural peel) formation (*chronic*)





They are not sharply defined, but represent
a *continuum spectrum*

Table 1 Stages of empyema				
Stage	Phase	Characteristics	Status of Lung Parenchyma	Treatment
I	Exudative (Acute)	Pleural membrane thickening Fibrin deposition Presence of exudative fluid	Compliant Reexpansion possible with evacuation of fluid	Thoracentesis Closed-tube thoracostomy
II	Fibrinopurulent	Extensive fibrin deposition Pleural fluid becomes turbid or purulent Presence of loculated empyema	Partial compliance Lung entrapment due to fibrin deposition	Closed-tube thoracostomy with fibrinolytics Thoracoscopy Thoracotomy
III	Organized (Chronic)	Fibroblast in growth Thickened pus Granulation tissue replacement of the pleural space	No compliance Lung completely entrapped by fibrous peel	Thoracotomy (decortication) Open drainage (Eloesser) Open thoracostomy




EUROPEAN SOCIETY OF THORACIC SURGEONS
ESTS

The transition through the 3 phases
occurs over a 3 to 6 week period




1° stage: exudate

increased capillary vascular permeability
proinflammatory cytokines production
(*IL-8; TNF α*)
facilitate fluid entry into pleural cavity
(*free-flowing exudate, normal pH, no
bacteria, \downarrow LDH \downarrow glucose*)



Antibiotics usually control the disease



If appropriate medical treatment is
not started (or delayed)...
progression to fibrinopurulent stage

Bacterial invasion
Increased fluid accumulation
Fibrin deposition
Septa development
(pH<7.20; glucose<2.2 mmol/l;
LDH> 1000U/l; WBC> 5000mm³)




If not drained, increased amount of bacteria appears and the fluid becomes frankly purulent, giving rise to a **true EMPYEMA**



EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS




Loculations prevent the extension of the infectious process to the whole pleura but make its evacuation by non-surgical means progressively difficult



Stage 3:

fibroblast migrate in the pleural cavity and produce an inelastic membrane (pleural peel or cortex) and entrapp the lung rendering it functionless





THORACIC SURGEONS



EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS




Causes of Thoracic Empyema

Parapneumonic Effusions:	40% to 60%
Post-thoracotomy:	20%
Post-traumatic:	4% to 10%
Idiopathic:	9%
Other causes:	5% to 10%



Pleural empyema bacteriology



Pathogens isolated
have significantly
changed
since the
introduction of
antibiotic therapy
in the 1940s





1917-1919

EUROPEAN SOCIETY OF THORACIC SURGEONS
ESTS

Empyema Commission Recommendations:

adequate pus drainage
proper nutritional support
pleural space obliteration







EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS

1917-1919

Empyema Commission Recommendations:

mortality reduced to 4.3%
in the later stage of the epidemic





EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS

Before antibiotics:


60%-70%: *Streptococcus Pneumoniae*
(now < 10%)

After antibiotics:

1950's: *Staphylococcus Aureus*

Now: *anaerobic infections*
Gram-negative organisms





EUROPEAN SOCIETY OF THORACIC SURGEONS
ESTS


Common organisms

Community-acquired

- Streptococcus* spp. (~ 52%)
 - ▶ *S. milleri*
 - ▶ *S. pneumoniae*
 - ▶ *S. intermedius*
- Staphylococcus aureus* (11%)
- Gram-negative aerobes (9%)
 - ▶ Enterobacteriaceae
 - ▶ *Escherichia coli*
- Anaerobes (20%)
 - ▶ *Fusobacterium* spp.
 - ▶ *Bacteroides* spp.
 - ▶ *Peptostreptococcus* spp.
 - ▶ Mixed

Hospital-acquired

- Staphylococci
 - ▶ Meticillin-resistant *S. aureus* (MRSA) (25%)
 - ▶ *S. aureus* (10%)
- Gram-negative aerobes (17%)
 - ▶ *E. coli*
 - ▶ *Pseudomonas aeruginosa*
 - ▶ *Klebsiella* spp.
- Anaerobes (8%)



Fungal empyema is very rare
($<1\%$ of all empyemas)

Candida species is the
commonest responsible
(usually in immunosuppressed pts)

High mortality ($> 70\%$)



EUROPEAN SOCIETY OF THORACIC SURGEONS
ESTS

MANAGEMENT



Pier Luigi Filosso, MD
University of Torino, Department of Thoracic Surgery




General rules

EUROPEAN SOCIETY OF THORACIC SURGEONS
ESTS

The *sine qua non* of empyema management is:
early
adequate
dependent drainage



Pleural empyema management depends on the stage at which it's diagnosed



EUROPEAN SOCIETY OF THORACIC SURGEONS
ESTS



Diagnostic challenge

EUROPEAN SOCIETY OF THORACIC SURGEONS
ESTS

To distinguish pleural effusions that will respond to antibiotic therapy **ALONE** from those that need chest drainage or surgery





Stage 1 disease



EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS

Stage 1

Antibiotics

Pleural effusion drainage



Antibiotics

EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS



An early and appropriate antibiotic treatment for the pneumonia minimizes the development of parapneumonic effusions and aborts the progression to complicated effusions or empyema



Antibiotics

EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS



Simple parapneum. effusions
no longer than that indicated
for the underlying pneumonia



Antibiotics

Diagnosis and Management of Parapneumonic Effusions and Empyema

Steve A. Sahn

Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, Medical University of South Carolina, Charleston

Approximately 1 million patients develop parapneumonic effusions (PPEs) annually in the United States. The outcome of these effusions is related to the interval between the onset of clinical symptoms and presentation to the physician, comorbidities, and timely management. Early antibiotic treatment usually prevents the development of a PPE and its progression to a complicated PPE and empyema. Pleural fluid analysis provides diagnostic information and guides therapy. If the PPE is small to moderate in size, free-flowing, and nonpurulent (pH, >7.30), it is highly likely that antibiotic treatment alone will be effective. Prolonged pneumonia symptoms before evaluation, pleural fluid with a pH <7.20, and loculated pleural fluid suggest the need for pleural space drainage. The presence of pus (empyema) aspirated from the pleural space always requires drainage. Fibrinolytics are most likely to be effective during the early fibrinolytic stage and may make surgical drainage unnecessary. If pleural space drainage is ineffective, video-assisted thoracic surgery should be performed without delay.

EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS

β -lactam antibiotics:
Amoxicillin/Clavulanate
Ticarcillin/Clavulanate
Piperacillin/Tazobactam
Ampicillin/Sulbactam
Quinolones
Imipem
Meropenem




Effusions drainage

EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS

Thoracentesis is usually sufficient to drain simple and limited pleural effusions without bacterial infiltration






Effusions drainage

EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS



>25% culture-positive parapneumonic effusions in the Stage 1 may respond to thoracentesis

Pneumonia caused by *Staphylococcus aureus* are less like to respond because of early loculations



Stage 2 disease



EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS

Stage 2

Antibiotics

Chest tube drainage

VATS



EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS

Chest tube placement

Decision is based on:

- pleural fluid characteristics
- absence of multiple loculations
- frank pus
- bacteria on pleural fluid Gram's stain
- pleural glucose < 40 mg/dl
- LDH > 1000 IU
- pH < 7.10





EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS



NO


Chest tube placement

Chest tube **MUST** be placed at the most dependent level and **MUST** enter the fluid collection



EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS



Chest tube placement


Chest tube **MUST** be placed at the most dependent level and **MUST** enter the fluid collection



NO

ATTENTION!!!!

Don't place the drain too much below, to avoid severe injuries...



Chest tube placement

Success rates may vary between
6% and 78%

To be successful the drainage
should be reserved for patients with
exudative
early fibrinopurulent effusions



Chest tube placement

Success rates deteriorate to
35% - 39% in case of true empyema





Which drainage?



EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS

24 Ch



Large bore catheters

20 Ch





EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS

Small bore catheters

12 Ch

10 Ch



EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS

Which drainage?


Traditionally, closed chest tube drainage
of pus with large bore drains
is done without radiological
guidance



EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS

Large bore drains





EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS

Which drainage?

Small bore catheters (10 – 14 Ch)
have been employed

Easier and less traumatic to insert



EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS

Which drainage?

Chest drain insertion
(especially small bore one)
is recommended
to be performed under image guidance



Drainage placement under ultrasonographic guidance



Under CT guidance (multiloculated effusions)






Which drainage?

EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS



Chest tube should be chosen according to the parapneumonic radiologic appearance...



7/06/2013 Ora esame 14.46 TORACE PA

EUROPEAN SOCIETY OF THORACIC SURGEONS


ESTS

before

after



Small bore drains



EUROPEAN SOCIETY OF THORACIC SURGEONS
ESTS

Reported success rates up to
83% - 87%

Drains are better tolerated
by the patients, but they're
more prone to obstruction
by fibrinous debris

Resolution tends to be slower
with chest duration: 7-26 days



EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS



Despite proper positioning
and aggressive drainage
management, small bore
chest tube may fail if it is
repeatedly occluded by
debris



Which drainage?

EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS

BTS guidelines

Management of pleural infection in adults: British Thoracic Society pleural disease guideline 2010

Helen E Davies,^{1,2} Robert J O Davies,¹ Christopher W H Davies,² on behalf of the BTS Pleural Disease Guideline Group

¹Oxford Centre for Respiratory Medicine, Churchill Hospital Site, Oxford Radcliffe Hospital, Oxford, UK

²Department of Respiratory Medicine, Royal Berkshire Hospital, Reading, UK

Correspondence to

Dr Christopher Davies,
Department of Respiratory
Medicine, Royal Berkshire
Hospital, Reading RG1 5AN, UK;
chris.davies@royalberkshire.
nhs.uk

INTRODUCTION

Pleural infection is a frequent clinical problem with an approximate annual incidence of up to 80 000 cases in the UK and USA combined. The associated mortality and morbidity is high; in the UK 20% of patients with empyema die and approximately 20% require surgery to recover within 12 months of their infection.^{1 2} Prompt evaluation and therapeutic intervention appears to reduce morbidity and mortality as well as healthcare costs.³

This article presents the results of a peer-reviewed systematic literature review combined with expert opinion of the preferred management

to *Streptococcus pneumoniae* which now only accounts for approximately 10% of culture-positive cases.⁶ The prevalence of *Staphylococcus aureus* rose and the development of staphylococcal resistance in the 1950s increased complications and mortality.^{7 8} More recently, the reported prevalence of anaerobic infections^{7 9 10} and Gram-negative organisms^{9 10} has risen. Use of intrapleural fibrinolytic therapy was first suggested in 1949¹¹ but the impure agents available caused adverse reactions. Most recently, early use of video-assisted thoracoscopic surgical (VATS) techniques has been introduced.¹²



EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS

Which drainage?

There's no clear consensus about the optimal chest drain size...

Surgeons tend to use large bore ones to avoid their blockage

ACCP and BTS guidelines recommend 10-14 Ch drains, since they're atraumatic and better tolerated by the patients compared to large bore ones



EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS



Following insertion, a pleural suction system (usually -20 cm H₂O) is used to facilitate pleural apposition

Predicting Factors for Outcome of Tube Thoracostomy in Complicated Parapneumonic Effusion or Empyema*

Hsu-Chia Huang, MD; Han-Yu Chang, MD; Chang-Wen Chen, MD;
Cheng-Hung Lee, MD; and Tzuen-Ren Hsiue, MD

Study objectives: To determine the predicting factors for outcome of tube thoracostomy in patients with complicated parapneumonic effusion (CPE) or empyema.

Design and settings: Retrospective chart review over a 55-month period at a tertiary referred medical center.

Patients and measurements: The medical charts of patients with empyema or CPE were reviewed. Data including age, gender, clinical symptoms, important underlying diseases, leukocyte count, duration of preadmission symptoms, interval from first procedure to second procedure, the time from first procedure to discharge (recovery time), the amount of effusion drained, administration of intrapleural streptokinase, chest tube size and position, loculation of pleural effusion, and characteristics and culture results of pleural effusion were recorded and compared between groups of patients with successful and failed outcome of tube thoracostomy drainage.

Results: One hundred twenty-one patients were selected for study. One hundred of these patients had received tube thoracostomy drainage with 53 successful outcomes and 47 failed outcomes of chest tube drainage. Nineteen patients received decortication directly, and the other two received antibiotics alone. Univariate analysis showed that pleural effusion leukocyte count, effusion amount, and loculation of pleural effusion were significantly related to the outcome of chest tube drainage. Multiple logistic regression analysis demonstrated that loculation and pleural effusion leukocyte count $\leq 6,400/\mu\text{L}$ were the only independent predicting factors related to failure of tube thoracostomy drainage.

Conclusions: Loculation and pleural effusion leukocyte count $\leq 6,400/\mu\text{L}$ were independent predicting factors of poor outcome of tube thoracostomy drainage. These results suggest that if the initial attempt at chest tube drainage fails, early surgical intervention should be considered in good surgical candidates with loculated empyema or pleural effusion with leukocyte count $\leq 6,400/\mu\text{L}$.

(CHEST 1999; 115:751-756)

Key words: complicated parapneumonic effusion; empyema; predicting factors; tube thoracostomy

Abbreviations: AROC = area under the receiver operating characteristic curve; CI = confidence interval; CPE = complicated parapneumonic effusion; D24 = the volume of pleural effusion drained from the chest tube within the first 24 h; LDH = lactate dehydrogenase; PMN = polymorphonuclear leukocyte; TNF = tumor necrosis factor

Retrospective review of 100 pts
managed by tube thoracostomy:

53%: resolution without other
interventions

Independent predictors of failure:
loculated empyema
pleural fluid leukocyte $< 6400\mu\text{g}/\text{L}$





EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS



Intrapleural instillation of
fibrinolytic agents have been
advocated in case of failure of
resolution with chest tube
placement



Table 2
Randomized clinical trials investigating intrapleural fibrinolytic therapy for empyema

Author	Number of Patients	Success (%)	Complications (%)
Bouros et al ¹⁰	Streptokinase group = 25 Urokinase group = 25	Streptokinase group = 92 Urokinase group = 92	28 developed elevation in temperature
Davies et al ¹¹	Streptokinase group = 12 Control = 12	Streptokinase group = 100 Control = 83	None
Tuncozgun et al ¹²	Urokinase group = 25 Control = 24	Urokinase group = 71 Control = 40	None
Diacon et al ¹³	Streptokinase group = 22 Control = 22	Streptokinase group = 82 Control = 48	None
Maskell et al ¹⁴	Streptokinase group = 208 Control = 222	Streptokinase group = 69 Control = 73	7 (chest pain, fever)
Misthos et al ¹⁵	Streptokinase group = 57 Control = 70	Streptokinase group = 88 Control = 67	None



Surgical versus non-surgical management of pleural empyema (Review)

Coote N, Kay ES



EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS

Fibrinolytic therapy reduced
the need for surgery when
compared with chest tube
placement alone

(RR 0.63; 95% CI: 0.46-0.86)

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in *The Cochrane Library*
2009, Issue 3

<http://www.thecochranelibrary.com>



BTS guidelines

Management of pleural infection in adults: British Thoracic Society pleural disease guideline 2010

Helen E Davies,^{1,2} Robert J O Davies,¹ Christopher W H Davies,² on behalf of the BTS Pleural Disease Guideline Group

INTRODUCTION

Pleural infection is a frequent clinical problem with an approximate annual incidence of up to 80 000 cases in the UK and USA combined. The associated mortality and morbidity is high; in the UK 20% of patients with empyema die and approximately 20% require surgery to recover within 12 months of their infection.^{1,2} Prompt evaluation and therapeutic intervention appears to reduce morbidity and mortality as well as healthcare costs.³

This article presents the results of a peer-reviewed systematic literature review combined with expert opinion of the preferred management

to *Streptococcus pneumoniae* which now only accounts for approximately 10% of culture-positive cases.⁶ The prevalence of *Staphylococcus aureus* rose and the development of staphylococcal resistance in the 1950s increased complications and mortality.^{7,8} More recently, the reported prevalence of anaerobic infections^{7,9,10} and Gram-negative organisms^{9,10} has risen. Use of intrapleural fibrinolytic therapy was first suggested in 1949¹¹ but the impure agents available caused adverse reactions. Most recently, early use of video-assisted thoracoscopic surgical (VATS) techniques has been introduced.¹²


¹Oxford Centre for Respiratory Medicine, Churchill Hospital Site, Oxford Radcliffe Hospital, Oxford, UK

²Department of Respiratory Medicine, Royal Berkshire Hospital, Reading, UK

Correspondence to
Dr Christopher Davies,
Department of Respiratory
Medicine, Royal Berkshire
Hospital, Reading RG1 5AN, UK;
chris.davies@royalberkshire.nhs.uk

EUROPEAN SOCIETY OF THORACIC SURGEONS
ESTS

Current evidence does not support the routine use of intrapleural fibrinolytic agents





Fibrinolytic therapy

EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS

BTS guidelines

Management of pleural infection in adults: British Thoracic Society pleural disease guideline 2010

Helen E Davies,^{1,2} Robert J O Davies,¹ Christopher W H Davies,² on behalf of the BTS Pleural Disease Guideline Group

INTRODUCTION

Pleural infection is a frequent clinical problem with an approximate annual incidence of up to 80 000 cases in the UK and USA combined. The associated mortality and morbidity is high; in the UK 20% of patients with empyema die and approximately 20% require surgery to recover within 12 months of their infection.^{1,2} Prompt evaluation and therapeutic intervention appears to reduce morbidity and mortality as well as healthcare costs.³

This article presents the results of a peer-reviewed systematic literature review combined with expert opinion of the preferred management

to *Streptococcus pneumoniae* which now only accounts for approximately 10% of culture-positive cases.⁶ The prevalence of *Staphylococcus aureus* rose and the development of staphylococcal resistance in the 1950s increased complications and mortality.^{7,8} More recently, the reported prevalence of anaerobic infections^{7,9,10} and Gram-negative organisms^{9,10} has risen. Use of intrapleural fibrinolytic therapy was first suggested in 1949¹¹ but the impure agents available caused adverse reactions. Most recently, early use of video-assisted thoracoscopic surgical (VATS) techniques has been introduced.¹²

Physical decompression of
multiloculated pleural
collections causing
dyspnoea or resp. failure
when surgery is not
immediately feasible
or at high risk

¹Oxford Centre for Respiratory Medicine, Churchill Hospital Site, Oxford Radcliffe Hospital, Oxford, UK

²Department of Respiratory Medicine, Royal Berkshire Hospital, Reading, UK

Correspondence to
Dr Christopher Davies,
Department of Respiratory
Medicine, Royal Berkshire
Hospital, Reading RG1 5AN, UK;
chris.davies@royalberkshire.nhs.uk

Acute Hypoxemic Respiratory Failure Following Intrapleural Thrombolytic Therapy for Hemothorax*

Michael D. Frye, M.D., F.C.C.P.; Mikell Jarratt, M.D.; and Steven A. Sahn, M.D., F.C.C.P.

Intrapleural instillation of thrombolytic agents has been useful in the treatment of hemothorax when thoracostomy tube drainage is unsuccessful. We present a patient who developed acute hypoxemic respiratory failure following the intrapleural instillation of both streptokinase and urokinase 24 h apart. Hypoxemia most likely resulted from a direct effect of the products of fibrinolysis on the pulmonary circulation.

(Chest 1994; 105:1595-96)

CO=cardiac output; FDP=fibrin degradation products; PAP=pulmonary artery pressure; PCWP=pulmonary capillary wedge pressure

Complications of the therapeutic use of intrapleural thrombolytic agents are infrequent. Although intravascular administration has been associated with adult respiratory distress syndrome (ARDS) in two patients,^{1,2} intrapleural instillation has not been previously reported to lead to pulmonary complications. We recently observed a patient who developed two episodes of severe hypoxemia related to the instillation of two different thrombolytic agents.

EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS

Report of ARDS in a patient who received both urokinase and streptokinase for empyema







EUROPEAN SOCIETY OF THORACIC SURGEONS
ESTS

Surgery

Pier Luigi Filosso, MD
University of Torino, Department of Thoracic Surgery



Most patients require surgery to promote drainage because of the presence of viscous pleural fluid or multiple loculations

A detailed intraoperative photograph showing a thoracic surgical procedure. The image displays the internal thoracic cavity with various anatomical structures, including the lung and pleural space. Surgical instruments, such as forceps and a retractor, are visible, holding back muscle and soft tissue to provide a clear view of the operative field. The lighting is bright, highlighting the surgical site.

Delay in elective drainage may allow the creation of pleural peel, prolong the hospital stay and increase hospital costs



EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS

Indications to surgical drainage:



- Extent of loculations
- Patient's operability
- Lung capability to re-expand
- Possible BPF



Tips & Tricks:

EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS

Double lumen tracheal ventilation

(fundamental for VATS and thoractomy; also in case of BPF)

Postoperative pain control

(epidural analgesia)

Early pts deambulation

(portable suction devices)

Low weigh heparin subcutaneously





Tips & Tricks:

EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS



Aggressive chest physiotherapy
and incentive spirometry
to allow:

deep breath
cough
secretion removal
lung re-expansion



Suggestions:



Portable suction devices allow an early hospital discharge and patient can be safely managed **at home**





EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS



VATS is useful during the
fibrinopurulent stage of empyema

Breakdown of all loculations,
drainage of the gelatinous exudate,
removal of fibrin and thin peels from
the visceral pleura, allowing complete
lung re-expansion



Small "utility" mini-thoracotomy
is sometimes needed to achieve a
complete lung re-expansion





Through the mini-thoracotomy
a correct loculation debridement
is feasible and may be more
effective





Stage 3 disease



Stage 3

Thoracotomy





EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS



Early thoracotomy for pleural space infection evacuation is usually performed in the **initial phase of the organizing stage (Stage 3)**

Pleural surfaces are covered by an amorphous gelatinous fluid, but a true fibrous peel has not yet formed



Blunt finger dissection to disrupt the septations and allow access to the entire pleural space



Total elimination of fibrin membranes from the lung, diaphragm and parietal pleura


Facilitate immediate and full lung re-expansion



EUROPEAN SOCIETY OF THORACIC SURGEONS


ESTS





EUROPEAN SOCIETY OF THORACIC SURGEONS


ESTS




2 large bore chest drainages are placed at the end of intervention, one anteriorly, one posteriorly

Additional chest drains may be used to drain small inaccessible pleural areas

Drainages must be placed under suction (-20 cm H₂O)




before



after




Chronic empyema



In a chronic empyema the presence of dense pleural peel makes impossible the lung re-expansion

The lung is entrapped and the pleural space obliteration is impossible



The result of a chronic
empyema is frequently a
fibrothorax



Causes of Chronic Empyema

Delay in diagnosis

Inadequate drainage in acute stage

Continuing reinfection (bronchopleural fistula)


Retained haemothorax

Specific infections (i.e.: tuberculosis or fungal infection)



EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS






In an acceptable surgical candidate
decortication remains the
procedure of choice

An alternative is **rib resection** and
large bore chest tube placement




Rib resection and drainage





The tube may be slowly retracted over the course of weeks or months, while the infected space heals behind it

The patient may be managed also as outpatients, with a close surveillance




Postoperative chest X-ray



EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS



Open window

Pier Luigi Filosso, MD
University of Torino, Department of Thoracic Surgery





EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS

Open window is the treatment of choice in case of debilitated patient with chronic empyema

It's imperative to place the window at the inferior aspect of the cavity and to make the chest wall opening large enough to accomodate one's fist



ATTENTION!!!

Open window thoracostomy
tends to close spontaneously



EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS

Special issue:

Postpneumonectomy empyema

Pier Luigi Filosso, MD
University of Torino, Department of Thoracic Surgery



Prevention

EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS



PREVENTION
IS BETTER
THAN CURE

Treat the bronchial stump with respect

Avoid devascularization

Avoid excessive length


Cover the stump with pleura or pericardium or muscle if preop. RT/CT has been done



Incidence

EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS



The overall BPF incidence is estimated to be between **1.6%** and **2.7%**, and 2/3 of these patients received induction chemo/radiotherapy



Symptoms

EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS



Early BPF occurs within few days
or up to 1 – 2 weeks after a
pneumonectomy

frothy pink sputum
air fluid level on chest X-ray
persistent low-grade fever
persistent clinical complaints

Bronchoscopy confirm the
suspect of BPF




Treatment goals:

EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS

Secure close the bronchial stump
obliterate the empyema cavity

Immediate re-exploration with
stump closure and reinforcement
with a pedicled muscle flap
(*intercostal, latissimus dorsi,*
serratus anterior, pectoralis major)
and pleural space drainage
(*Clagett & Geraci procedure*)





EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS

Predictors of Successful Closure of Open Window Thoracostomy for Postpneumonectomy Empyema

Fabio Massera, MD, Mario Robustellini, MD, Claudio Della Pona, MD, Gerolamo Rossi, MD, Adriano Rizzi, MD, and Gaetano Rocco, MD, FRCS (Ed)

Division of General Thoracic Surgery, "E. Morelli" Regional Hospital, Sondalo, Division of General Thoracic Surgery, Humanitas Gavazzeni Hospital, Bergamo, and Division of General Thoracic Surgery, National Cancer Institute, Pascale Foundation, Naples, Italy

Background. Although the open window thoracostomy (OWT) represents the ideal method for drainage of post-pneumonectomy empyema (PPE), several controversies exist concerning its closure.

Methods. Between January 1993 and December 2003, an OWT was created in 31 patients (29 male and 2 female) with PPE. The median age was 61 years (range, 32 to 76). In 26 patients (84%) a bronchial stump fistula developed. The OWT closure was correlated with characteristics of PPE and the timing of OWT.

Results. In 15 patients (48%), the OWT could be closed by obliteration of pleural cavity with antibiotic solution (3 patients) or intrathoracic muscle transposition (12 patients). A successful closure was observed in 13 of the 15 patients (87%). All patients closed by Clagett's procedure remained empyema free. Recurrent cancer ($n = 4$), poor functional status ($n = 3$), refusal of further opera-

tion ($n = 2$), and persistent tuberculous empyema ($n = 2$) were common causes of failure of OWT closure. Univariate analysis revealed that the timing of empyema development after surgery ($p = 0.02$) and the timing of OWT ($p = 0.03$) were significant predictors of thoracostomy closure.

Conclusions. Late onset of PPE and immediate OWT creation are significant predictors of OWT closure. Smaller dimensions of the pleural cavity appeared to increase the likelihood of closure. When the pleural cavity shows healthy granulation tissue and no bronchopleural fistula, the Clagett's procedure is safe and effective to obliterate the pleural cavity. Obliteration by muscle flap transposition can be reserved for patients with persistent or recurrent bronchopleural fistula.

(Ann Thorac Surg 2006;82:288-92)

© 2006 by The Society of Thoracic Surgeons


Massera and Coll advocated an early open window thoracostomy for BPF

Late BPF presentation and early open window procedure were independent predictors of successful BPF management



Chest tube management





EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS

One or two chest tubes are placed at the end of surgery and left under suction ($-20 \text{ cm H}_2\text{O}$)

They can be removed when there are:

no signs of infection

no more pus

no more than 100 ml-150 ml /24 h

no air leaks



In case of persistent serous fluid, the drain may be connected with an Heimlich valve, making the patient able to walk and to be discharged from the hospital



EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS

Be careful not to remove too soon
the drains....

Fast-track surgery does not exist in case of
pleural empyema





EUROPEAN SOCIETY OF THORACIC SURGEONS
ESTS



Conclusions

Турин, Италия

Pier Luigi Filosso, MD
University of Torino, Department of Thoracic Surgery



Early intervention of pleural space infection is the key to prevent chronic empyema

The advent of VATS made it possible to treat stage I and stage II empyema with significantly less morbidity

Management of chronic empyema remains a major challenge in Thoracic Surgery



EMPYEMA NEEDS TO BE
TREATED AND MANAGED
URGENTLY, TO AVOID THESE
CONSEQUENCES...




FIGURE 109.—Comparative results of management of empyema in World Wars I and II. A. Typical patients with chronic empyema in Zone of Interior hospitals in World War I (2).

EUROPEAN SOCIETY OF THORACIC SURGEONS
ESTS



EUROPEAN SOCIETY OF THORACIC SURGEONS
ESTS



Thank you very much
for your attention...

Турин, Италия

Pier Luigi Filosso, MD
University of Torino, Department of Thoracic Surgery



EUROPEAN SOCIETY OF THORACIC SURGEONS

ESTS

Pier Luigi Filosso, MD
University of Torino, Department of Thoracic Surgery